Figure 1
Figure 1. Effect of anti-Ly49C/I and anti-Ly49G2 treatment on the frequency of NK Ly49 subsets in various strains of mice. Mice received 300 μg mAb 5E6 (anti-Ly49C/I), mAb 4D11 (anti-Ly49G2), or rat IgG for 2 consecutive days. Spleen cells were then assessed by 5-color flow cytometric analysis for Ly49C/I or Ly49I and Ly49G2 expression on NK cells as described in “Flow cytometric analysis.” (A) Representative dot plots for NK cell (CD45+NK1.1+CD3−) in spleen cells are presented. (B) Total number of CD45+NK1.1+CD3− after antibody depletion. (C) Frequency of Ly49C/I (5E6) and Ly49I (YLI-90) in control B6 and B10.D2 mice. (D) Distribution of Ly49G2 (Cwy-3) and Ly49I (YLI-90) NK subsets after antibody treatment in B6 and B10.D2 mice. Data are representative of 3 experiments (mean ± SEM). Two-way ANOVA was done to assess significance (P < .05).

Effect of anti-Ly49C/I and anti-Ly49G2 treatment on the frequency of NK Ly49 subsets in various strains of mice. Mice received 300 μg mAb 5E6 (anti-Ly49C/I), mAb 4D11 (anti-Ly49G2), or rat IgG for 2 consecutive days. Spleen cells were then assessed by 5-color flow cytometric analysis for Ly49C/I or Ly49I and Ly49G2 expression on NK cells as described in “Flow cytometric analysis.” (A) Representative dot plots for NK cell (CD45+NK1.1+CD3) in spleen cells are presented. (B) Total number of CD45+NK1.1+CD3 after antibody depletion. (C) Frequency of Ly49C/I (5E6) and Ly49I (YLI-90) in control B6 and B10.D2 mice. (D) Distribution of Ly49G2 (Cwy-3) and Ly49I (YLI-90) NK subsets after antibody treatment in B6 and B10.D2 mice. Data are representative of 3 experiments (mean ± SEM). Two-way ANOVA was done to assess significance (P < .05).

Close Modal

or Create an Account

Close Modal
Close Modal